Karissa A. Laur Director, Prescription Assistance Programs Coordinating Patient Assistance Programs with Medicare Part D: A Manufacturer’s Perspective.

Slides:

Advertisements

Similar presentations

Dual Eligible and Low-Income Medicare Beneficiaries and Part D Presentation to National Medicaid Congress by Andy Schneider, Senior Advisor June 5, 2006.

Advertisements

Part Ds Low-Income Benefits: Theory and Reality Marc Steinberg, Families USA Health Action 2006 January 26, 2006 ** Washington, DC

Medicare Prescription Drug Discount Card Ranjani Varadarajan PYPC 7810.

SoonerCare Update Interim study- Senate HHS- Sep.29, 2014.

DataBrief: Did you know… DataBrief Series ● February 2011 ● No. 12 Dual Eligibles Across the States In 2008, dual eligibles as a percent of the total Medicare.

Avalere Health LLC | The intersection of business strategy and public policy Long-Term Care Financing Reform: A Federal and Private Insurance Partnership.

Adam J. Falk, Esq. FELDESMAN TUCKER LEIFER FIDELL LLP Legal issues for Medicaid Plans Under Part D in Serving Dual Eligibles MEDICAID HEALTH PLANS OF AMERICA.

Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.

Y0096_MRK_OK_PDSALPRE15 APPROVED bcbsok.com Your presenter today: Bob Archer Health Insurance Enrollment Center.

2006 Retiree MIP Overview October 2006 Rajiv Nundy & Kent Humphries HR Compensation Management.

The Evolving Role of States in the Medicare Drug Benefit Thomas M. Snedden, Director Pennsylvania PACE Program The Third National Medicare Congress October.

Supplementing PACE through Medicare Part D

Pharmaceutical Assistance Contract for the Elderly (PACE) Program began July 1, 1984 PACE Needs Enhancement Tier (PACENET) Program began January 1, 1997.

Ideas for People Losing Illinois Cares Rx Benefits July 2011.

Medicare Part D and HIV/AIDS: What a Clinician May Want to Know Laura Cheever, M.D., ScM Deputy Director, Chief Medical Officer HIV/AIDS Bureau Health.

Disability Program Manager

THE AIDS INSTITUTE The AIDS Institute HEALTH REFORM AND ADAP Emily McCloskey, Public Policy Associate Carl Schmid, Deputy Executive Director AIDS Drug.

Meeting the Medication Needs of Iowans: the IowaCare Pilot Pharmaceutical Program and UIHC Medication Assistance Center Lisa Mascardo, PharmD Assistant.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.

Return to KaiserEDU Tutorials

Medicare and the New Prescription Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser.

Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family Foundation for NASI Annual Conference.

The Medicare Prescription Drug Benefit Program Medicare Part D P & T Committee Meeting Virginia Department of Medical Assistance Services August 31, 2005.

Exhibit 1 NOTE: *Amount corresponds to the estimated catastrophic coverage limit for non-low-income subsidy enrollees ($6,734 for LIS enrollees), which.

Medicare Prescription Drug Coverage Extra Help with Medicare Prescription Drug Costs for Those Who Need it Most.

Medicare Prescription Drug Coverage. What’s Different About Prescription Drug Information? One size does not fit all, more than ever before Distinct messages.

Joint Informational Hearing The Federal Medicare Prescription Drug Act: State Readiness, Implementation, and Consumer Issues Bonnie Burns, Training and.

Agenda Trends in the Senior Market Part D Benefits & Guidelines

MEDICARE PRESCRIPTION DRUG BENEFIT Presented by Juliette Cubanski, Ph.D. Principal Policy Analyst Medicare Policy Project The Henry J. Kaiser Family Foundation.

1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?

Medicare Prescription Drug Benefit: Part D Health & Disability Advocates Stephanie Altman, J.D Ext

Jeffrey Levi, Ph.D. American Public Health Association Annual Meeting November 8, 2004 Options for enhancing quality and equity in the CARE Act: If not.

1 Medicare Prescription Drug Improvement and Modernization Act & Beneficiaries With Mental Illnesses Presentation to NAMI Convention June 19, 2005 Andrew.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Roy Trudel, CMSO National Eligibility Workers Association 07/12/05.

MEDICARE PART D Are We Ready? Are We Ready?. Medicare Part D Overview Medicare Part A and B covers individuals Age 65 and older Age 65 and older Those.

Medicare Update Presented by Tricia Neuman, Sc.D. Vice President, Henry J. Kaiser Family Foundation for Grantmakers in Health November 4, 2004.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy.

Slide -1 Medicare Prescription Drug Benefit Denise S. Stanley, Pharm.D. Atlanta Regional Office Centers for Medicare & Medicaid Services March 17, 2006.

State Strategies: Expanding Prescription Drug Access Dee Mahan Families USA November 1, 2002.

Summary of the Future of Medicaid Long-Term Care Services in PA: A Wakeup Call Report cosponsored by University of Pittsburgh Institute of Politics & the.

Overview of the Maryland Primary Adult Care (PAC) Program Rhode Island Policy Makers Breakfast November 17, 2010 Stacey Davis Deputy Director of Planning.

Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.

The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.

THE COMMONWEALTH FUND Medicare Part D: What Are The Concerns? Stuart Guterman Director, Program on Medicare’s Future The Commonwealth Fund Association.

11/8/051 Medicare Prescription Drug Benefits Employee Workshop November 2005.

Return to Tutorials Tricia Neuman, Sc.D. Director, Medicare Policy Project Vice President, Kaiser Family Foundation For KaiserEDU June 2009 Medicare 101:

Helping People Eligible for Extra Help What You Need to Know about LIS National Medicare Training Program Audio-conference Training September 26, 2007.

Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.

The Potential Impact of Health Care Reform on California: Consumer Affordability Dylan H. Roby, Ph.D. Assistant Professor of.

Exhibit 1 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. MA-PD is Medicare Advantage Prescription Drug Plan. Analysis includes non-LIS.

Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.

Figure 1 K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Dual Eligibles: The Basics Barbara Lyons, Ph.D. Director, Kaiser Commission on.

1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.

1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 Long-Term Care: Exploring the Possibilities Diane Rowland, Sc.D. Executive Vice.

Benefit Programs Which Can Help You Transition to Employment Concurrent Session 2C Advancing Inclusion: The Future of State Government for Persons with.

Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.

Medicare Prescription Drug Congress MMA and Medicaid Gale Arden Director, Disabled & Elderly Health Programs Group CMSO CMS October 2005.

Estimating the Cost of the Medicare Drug Benefit Philip Ellis Steve Lieberman Medicare Prescription Drug Congress February 27, 2004.

MEDICARE PART D July MEDICARE PART D: OVERVIEW Part D provides prescription drug coverage for Medicare beneficiaries. Prescription drug plans compete.

Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.

AFFORDABLE CARE ACT CONSUMER IMPACT. WHAT’S CHANGING WITH THE ACA? What’s not changing with the ACA? Will have broad impact that affects some population.

State Responses to Medicare Part D Presented by: Kimberley Fox, Senior Policy Analyst, Institute for Health Policy Academy Health Annual Research Meeting.

Health Reform: An Overview Unit 4 Seminar. The Decision The opinions spanned 193 pages, upholding the individual insurance mandate while reflecting a.

Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.

2018 Medicare Prescription Drug Benefit

Director, Pennsylvania PACE Program National Medicare Congress

Drug Industry Efforts:

Part D Plan Perspective on Serving Dual Eligibles

Presentation transcript:

Karissa A. Laur Director, Prescription Assistance Programs Coordinating Patient Assistance Programs with Medicare Part D: A Manufacturer’s Perspective June 5, 2006

Background Over the past 28 years, AstraZeneca has worked hard to better understand the needs of patients and the health care system so that our programs can make a difference. AstraZeneca offers a variety of patient assistance programs: AstraZeneca Foundation PAP, Caring Partners Program, Together Rx Access and PPARx. As a result, in 2005, through the AstraZeneca patient assistance programs, we provided more than $751 million in savings to more than 712,000 patients without drug coverage throughout the US and Puerto Rico.

Value of Medicare Part D Coverage for both brand name and generic prescription medicines. A choice of prescription plans that offer savings on a variety of prescription medicines right at the pharmacy counter or through a mail-order pharmacy. People with limited incomes who qualify for extra help have continuous drug coverage and pay only a small amount for each prescription. Coverage for future medication needs and protection against increased drug costs.

Value of Medicare Part D Beneficiaries who had limited or no drug coverage prior to ’06 – nearly 21 million people – now have access to multiple medicines through Part D According to the Kaiser Family Foundation, most beneficiaries will save money by using the Part D benefit Approx. 64% of beneficiaries are expected to reduce out-of-pocket spending by an average of $919 (excluding premiums)

Patient Assistance in Part D: Who May Need It? Low-income populations (<150% FPL) that do not qualify for extra help due to assets and do not qualify for other assistance that counts towards TrOOP Approx million Part D estimated enrollees below 250% FPL expected not to receive the low- income subsidies About 4.3 million of those are expected to reach the Part D initial coverage limit About 40% of the population that reaches initial coverage limit, or 1.7 million, are expected to reach catastrophic coverage

Variety of Factors to Consider Recent surveys report most patients pleased with the benefit/savings Part D plan designs and pharmacist incentives heavily favor generic utilization for patients who experience cost challenges Recent OIG opinion created an opportunity for manufacturers to reassess their views on Part D enrollees participating in traditional PAPs CMS comments and guidance is supportive of manufacturer efforts to help Part D enrollees

AstraZeneca Offerings in Support of Part D Broad access philosophy to Medicare contracting Industry leading Medicare Part D Education and Outreach Enhanced PAP program for patients Supporting LIS enrollment Offering choice for low-income patients who choose not to enroll Interim assistance for those enrolled in Part D experiencing financial challenges Developing assistance solution that works at the pharmacy

AstraZeneca Approach to Patient Assistance Provide a more meaningful patient experience for all program enrollees For Medicare eligible patient –Focus on the near-term, but create options that allow us the flexibility to adjust the process –Provide substantive assistance to help the patient through the Part D transition process –Take particular care of our existing patient population Develop sustainable solutions

AstraZeneca PAP Enhancements Expand PAP FPL to 250% – Individual = $24,500 – Couple = $33,000 – Family of four = $50,000 Streamline application process Expand temporary enrollment Provide case management services for all patients

AstraZeneca PAP Enhancements Apply a three-pronged approach for Medicare eligible patient assistance as an interim solution LIS-eligibles –Develop a front-end interface for PAP to case manage LIS-eligibles through the SSA process Part D Non-Enrollees –Allow those that are NOT eligible for LIS and that have NOT enrolled in Part D to continue to use PAP Part D Enrollees –Allow those that are enrolled in Part D and experiencing a financial challenge in affording their medicine to use PAP on an interim basis

Exploring Viable Long-Term Solutions AstraZeneca exploring our ability to offer a pharmacy-based model for patient assistance Pharmacy counter is where many will experience a financial burden that prevents them from getting their medicines We also have been working with other companies on a potential multi-company approach that works at the pharmacy counter